Moleculin Biotech (MBRX) Proxy filing summary

Executive summary

• Annual meeting scheduled for October 9, 2026, with voting available online or in person.

• Shareholders are encouraged to review proxy materials and annual report before voting.

Voting matters and shareholder proposals

• Election of five directors: Walter V. Klemp, Robert George, Michael Cannon, John Climaco, and Elizabeth Cermak.

• Ratification of Grant Thornton, LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval sought for amendment to the 2024 Equity Incentive Plan to increase authorized shares.

• Advisory vote on executive compensation (say-on-pay) included.

• Proposal to eliminate supermajority voting requirements for amending the Certificate of Incorporation.

• Proposal to authorize the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20.

• Authorization to adjourn the meeting to solicit additional proxies if needed.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and all proposals.

• Board to be granted authority for reverse stock split at its discretion within one year of the meeting.